Plain-English translation of NCT06384222 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new type of MRI scan using hyperpolarized carbon-13 can help doctors track how well abiraterone is working in men with high-risk prostate cancer before surgery. You would receive the medication for 12 weeks and undergo special imaging scans to measure changes in how cancer cells are using energy, which may predict how well the treatment is working.
Currently, doctors have limited ways to know early on whether this medication is working before surgery. This trial aims to find out if this new scanning technique can detect treatment response earlier, which could help guide treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would receive the medication abiraterone by mouth and for 12 weeks, given in three 4-week cycles. During this time, you would have three special MRI scans (at the start, midway through, and at the end of treatment), each involving an injection and a special coil placed briefly in the rectum for better imaging. After completing the medication, you would have surgery to remove your prostate, then return for follow-up visits every 3 months in the first year and every 6 months afterward for up to 5 years.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States